KEGG   DRUG: D03684Help
Entry
D03684                      Drug                                   

Name
Denosumab (genetical recombination) (JAN);
Denosumab (USAN);
Prolia (TN);
Ranmark (TN);
Xgeva (TN)
Product
Formula
C6404H9912N1724O2004S50
Exact mass
144631.2737
Mol weight
144720.8225
Activity
Prevention and treatment of all forms of osteoporosis or bone loss,  Monoclonal antibody [DS:H00010]
Remark
Therapeutic category: 
ATC code: 
Target
RANK-L inhibitor [HSA:8600] [KO:K05473]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04380  Osteoclast differentiation  
 
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 M MUSCULO-SKELETAL SYSTEM
  M05 DRUGS FOR TREATMENT OF BONE DISEASES
   M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
    M05BX Other drugs affecting bone structure and mineralization
     M05BX04 Denosumab
      D03684  Denosumab (genetical recombination) (JAN); Denosumab (USAN)
USP drug classification [BR:br08302]
 Metabolic Bone Disease Agents
  Denosumab
   D03684  Denosumab (genetical recombination) (JAN); Denosumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D03684  Denosumab (genetical recombination) (JAN); Denosumab (USAN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  TNF family
   RANKL
    Denosumab
     D03684  Denosumab (genetical recombination) (JAN); Denosumab (USAN)
BRITE hierarchy
Other DBs
CAS: 
615258-40-7
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system